Search Browse Earnings

Orgenesis Inc.

OTC:ORGS

Pharmaceutical Preparations·GERMANTOWN, MD

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Caplan Vered

Revenue

$36.0M

+13.8% YoY

FY 2023

Adj. EBITDA

-$8.1M

-22.6% margin

FY 2023

Net Income

-$14.9M

-41.3% margin

FY 2023

EPS (Diluted)

$0.59

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$5.3M

FY 2023

Total Debt

$145,000

FY 2021

Net Cash

$5.2M

FY 2021

Enterprise Value

—

Debt / EBITDA

0.6x

FY 2023

EV / EBITDA

—

Employees

—